Knowledge base
Targets, pipeline, trials and literature across every indication currently loaded.
2 diseases in scope
Diseases
Coverage across the ingested sources
Top targets
Ranked by gene-disease association score
| Gene | Disease | Score |
|---|---|---|
|
EGFR
epidermal growth factor receptor
|
non-small cell lung car… |
0.89
|
|
BRCA1
BRCA1 DNA repair associated
|
ovarian cancer |
0.88
|
|
BRCA2
BRCA2 DNA repair associated
|
ovarian cancer |
0.88
|
|
KRAS
KRas proto-oncogene, GTPase
|
non-small cell lung car… |
0.83
|
|
RAD51C
RAD51 paralog C
|
ovarian cancer |
0.83
|
|
ALK
ALK receptor tyrosine kinase
|
non-small cell lung car… |
0.81
|
|
ERBB2
erb-b2 receptor tyrosine kinase 2
|
non-small cell lung car… |
0.81
|
|
TP53
tumor protein p53
|
ovarian cancer |
0.81
|
|
ROS1
ROS proto-oncogene 1, receptor tyrosine kin…
|
non-small cell lung car… |
0.81
|
|
MET
MET proto-oncogene, receptor tyrosine kinase
|
non-small cell lung car… |
0.81
|
|
RAD51D
RAD51 paralog D
|
ovarian cancer |
0.80
|
|
DICER1
dicer 1, ribonuclease III
|
non-small cell lung car… |
0.79
|
|
BRIP1
BRCA1 interacting DNA helicase 1
|
ovarian cancer |
0.79
|
|
PIK3CA
phosphatidylinositol-4,5-bisphosphate 3-kin…
|
ovarian cancer |
0.79
|
|
RET
ret proto-oncogene
|
non-small cell lung car… |
0.78
|
|
TP53
tumor protein p53
|
non-small cell lung car… |
0.77
|
|
PALB2
partner and localizer of BRCA2
|
ovarian cancer |
0.77
|
|
BRAF
B-Raf proto-oncogene, serine/threonine kina…
|
non-small cell lung car… |
0.76
|
-
Early Phase 1 10 0.6%
-
Phase 1 294 17.9%
-
Phase 1/2 243 14.8%
-
Phase 2 671 40.9%
-
Phase 2/3 48 2.9%
-
Phase 3 267 16.3%
-
Pre-approval 2 0.1%
-
Approved 80 4.9%
-
Unknown 22 1.3%
Trials over time
Trial status mix
Recent trials
Most recently started studies
| Trial | Phase | Lead sponsor |
|---|---|---|
|
NCT07543172
Phase II Study of CIMAVAX-EGF in Combination With KRAS …
|
PHASE2 | Roswell Park Cancer Institu… |
|
NCT07541170
A Phase III, Randomized, Open-label Study Evaluating th…
|
PHASE3 | Hoffmann-La Roche |
|
NCT07322341
A Phase 2 Trial of SX-682 and Atezolizumab in Patients …
|
PHASE2 | University of Washington |
|
NCT07146230
The Selective Personalized Radio-Immunotherapy for Loca…
|
PHASE2 | Montefiore Medical Center |
|
NCT07135882
A Randomised Phase III Trial of Up-front Radiotherapy B…
|
PHASE3 | Trans Tasman Radiation Onco… |
|
NCT06943664
Phase II Trial: Photoimmunotherapy and Anti-PD1 in Pati…
|
PHASE2 | Roswell Park Cancer Institu… |
|
NCT07393555
A Randomized Phase II Study of Sacituzumab Govitecan Al…
|
PHASE2 | SWOG Cancer Research Network |
|
NCT05642195
Phase I/II Evaluation of a Cancer Lysate Vaccine and Mo…
|
PHASE1/PHASE2 | National Cancer Institute (… |
Most active sponsors
By number of trials in scope
| Company | Type | Trials |
|---|---|---|
| National Cancer Institute (NCI) | NIH | 598 |
| AstraZeneca | Industry | 325 |
| Merck Sharp & Dohme LLC | Industry | 251 |
| Eli Lilly and Company | Industry | 201 |
| Bristol-Myers Squibb | Industry | 167 |
| Hoffmann-La Roche | Industry | 148 |
| Pfizer | Industry | 142 |
| Genentech, Inc. | Industry | 139 |
| Novartis Pharmaceuticals | Industry | 130 |
| M.D. Anderson Cancer Center | Other | 103 |